US-based medical device company Atraverse Medical has said that it secured $12.5 million of total seed investment, demonstrating strong investor belief in the need for continued innovation in the left-heart access arena.
This financing includes investment from world-class physicians, reputable venture investors, and successful medtech entrepreneurs.
According to the company, this new funding will boost the firm’s research and development efforts as well as early commercialisation initiatives.
“The completion of our seed round positions Atraverse Medical for continued success in transforming the landscape of left-heart access,” John Slump, CEO/President and Co-Founder of Atraverse Medical, said in a statement.
Moreover, the company mentioned that it received US Food and Drug Administration (FDA) clearance of its HOTWIRE radiofrequency (RF) guidewire, a novel device that enables zero exchange left-heart access while also acting as a rail for catheter-based therapy systems.
“The FDA clearance of the HOTWIRE underscores our dedication to medical innovation and our commitment to improving the standard of care for procedures requiring transseptal access including endocardial ablation, left atrial appendage closure, and mitral valve repair,” said Dr Steven Mickelsen, Atraverse Co-Founder as well as a cardiac electrophysiology physician at Scripps Hospital in La Jolla, US.
Featuring universal sheath compatibility and optimised RF technology, the HOTWIRE aims to improve patient outcomes and streamline procedural workflows, the company said.